PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1990 no persons are equired to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1 of 3

Complete if Known				
Application Number	10/823,506			
Filing Date	April 12, 2004			
First Named Inventor	Carl G. Hellerqvist			
Group Art Unit	Not yet assigned   646			
Examiner Name	Not yet assigned Ruixian & Li			
Attorney Docket Number	22100-0202 (49530-299673)			

				U.S. PATENT DOCUMENT	S	
Examiner Initials	Cite No.1	U.S. Patent	Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RLI	1	4,242,326		Sugawara et al.	06-18-1979	
ł	2	5,010,062		Hellerqvist	09-25-1989	
	3	5,811,403		Hellerqvist	09-30-1996	
<b>—</b>	4	5,858,991		Hellerqvist et al.	01-29-1997	
RLi	5	5,939,396		Hellerqvist	02-24-1998	
				<u> </u>		
·			<del></del>			
						. — –
					<del></del>	
			<u> </u>			
	l					

Office³ Number⁴  WO 91/04048  WO 97/41844	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
WO 97/41844			<del></del>		
			11 12 1007		
			11-13-1997		L
WO   98/14603			04-09-1998		Ι
WO 98/32448			07-30-1998		Γ
WO 98/32452			07-30-1998		Τ
WO 98/32453			07-30-1998		Т
WO 98/40487			09-17-1998		N
					Т
1	WO 98/32448 WO 98/32452 WO 98/32453	WO 98/32448 WO 98/32452 WO 98/32453	WO 98/32448 WO 98/32452 WO 98/32453	WO 98/32448 07-30-1998 WO 98/32452 07-30-1998 WO 98/32453 07-30-1998	WO 98/32448 07-30-1998 WO 98/32452 07-30-1998 WO 98/32453 07-30-1998

	Examiner Signature	Rinding L	Date Considered	7/17/2006
--	-----------------------	-----------	--------------------	-----------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

		Complete if Known				
Substitute for Form 1449/A/PTO		Application Number	10/823,506			
1	NEODMATION DICCLOSUDE	Filing Date	April 12, 2004			
INFORMATION DISCLOSURE		First Named Inventor	Carl G. Hellerqvist			
STATEMENT BY APPLICANT		Group Art Unit	Not yet assigned 1646			
	(use as many sheets as necessary	Examiner Name	Not yet assigned Ruixiana Li			
Sheet	of	Attorney Docket Number	22100-0202 (49530-299673)			

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
RLi	13	DEVORE et al., "Phase I Study of the Antineovascularization Drug CM101," Clinical Cancer Research, Vol. 3, pp. 365-372 (1997)	
	14	FU, et al., "Expressional Cloning of CM101 Receptor Gene from Mammalian Cells,"  Proceedings of the American Association of Cancer Research, Abstract No. 3677, Vol. 40, p. 557 (1999)	
	15	GEARING, et al., "Expression Cloning of a Receptor for Human Granulocyte-Macrophage Colony-Stimulating Factor," The EMBO Journal, Vol. 8, No. 12, pp. 3667-3676 (1989)	
	16	HELLERQVIST et al., "Anti-Tumor Effects of GBS Toxin are Caused by Induction of a Targeted Inflammatory Reaction," Angiogenesis: Molecular Biology, Clinical Aspects, Edited by Maragoudakis et al., Plenum Press, New York, pp. 265-269 (1994)	
	17	HELLERQVIST et al., "Antitumor Effects of GBS Toxin: A Polysaccharide Exotoxin From Group B β-Hemolytic Streptococcus," J. Cancer Res. Clin. Oncol., Vol. 120, pp. 63-70 (1993)	
	18	HELLERQVIST et al., "Molecular Basis for Group B β-Hemolytic Streptococcal Disease," Proc. Natl. Acad. Sci. USA, Vol. 84, pp.51-55 (1987)	
	19	HELLERQVIST et al., "Preliminary Results of a Phase I Trial of CM101 in Cancer Patients," J. Cellular Biochemistry, Suppl. 19B, p. 26 (1995)	
	20	HELLERQVIST et al., "Studies on Group B β-Hemolytic Streptococcus. I. Isolation and Partial Characterization of an Extracellular Toxin," Pediatr. Res., Vol. 15. pp. 892-898 (1981)	
	21	HILLIER, et al., "zr59d01.rl Soares NhHMPu S1 Homo sapiens cDNA clone 667681 5' Similar to Tr:G507415 G507415 Brain Specific Na+-Dependent Inorganic Phosphate Cotransporter," Database EMBL – EMEST20 'Online!, Entry HS1173506, Acc. No. AA258513 (March 19, 1997)	
	22	KOVACS et al., "Fibrogenic Cytokines and Connective Tissue Production," The FASEB Journal, Vol. 8, pp. 854-861 (1994)	
	23	NORRBY, "Angiogenesis: New Aspects Relating to Its Initiation and Control," APMIS, Vol. 105, pp. 417-437 (1997)	
RL;	24	POLVERINI, "The Pathophysiology of Angiogenesis," Crit. Rev. Oral. Biol. Med., Vol. 6, No. 3, pp.230-247 (1995)	

Examiner Signature	Rusting	<i>-1</i>	Date Considered	7/17 pool

PTO/SB/088 (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/823,506 Filing Date April 12, 2004 **INFORMATION DISCLOSURE** First Named Inventor Carl G. Hellerqvist STATEMENT BY APPLICANT **Group Art Unit** Not yet assigned 1646 (use as many sheets as necessary Ruixiang **Examiner Name** Not yet assigned Attorney Docket Number 22100-0202 (49530-299673) Sheet of

<del></del>			
		OTHER INFORMATION, NON PATENT LITERATURE POCUMENTS	
	<del>,                                     </del>	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	т-
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Т
	25	QUINN, et al., "CM101, A Polysaccharide Antitumor Agent, Does Not Inhibit Wound Healing	
RLi	Į.	in Murine Models," J. Cancer Res. Clin. Oncol., Vol. 121, pp.253-256 (1995)	$\mathbb{N}$
ici		in Murine Models, 5. Cancer Res. Citi. Oncol., vol. 121, pp.255-250 (1995)	П
	26	THURMAN, et al., "Actue Inflammatory Changes in Subcutaneous Microtumors in the Ears of	$\Box$
RLI	ł	Mice Induced by Intravenous CM101 (GBS Toxin)," J. Cancer Res. Clin. Oncol., Vol. 122, pp.	
,		549-553 (1996)	
	27	WAMIL, et al., "Soluble E-Selectin in Cancer Patients as a Maker of the Therapeutic Efficacy of	
RL;		CM101, a Tumor-Inhibiting Anti-Neovascularization Agent, Elevated in Phase I Clinical Trail,"	
IV.		J. Cancer Res. Clin. Oncol., Vol. 123, pp. 173-179 (1997)	
	<u> </u>	J. Cancer Res. Can. Oncol., Vol. 123, pp. 173-179 (1997)	╁
	ļ		1
			T
	ļ		lacksquare
			1
			l
	<u> </u>		╁
			١
			T
			İ
			1
	<u> </u>		┼-
	İ		1
	ļ	· · · · · · · · · · · · · · · · · · ·	┼-
	<del> </del>		+
	1		
	Ь		

Examiner Rusciang L.	Date Considered	7/17/2006
----------------------	--------------------	-----------